Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study - 06/09/22
Doi : 10.1016/j.jinf.2022.06.018
Yue Yin a, 1, Xinjie Li a, 1, Chungen Qian b, Bangning Cheng b, Fengmin Lu a, Tao Shen a, ⁎ 
a Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing, China
b Peking University – YHLO Joint Laboratory for Molecular Diagnostics of Infectious Diseases, Peking University, Beijing, China
⁎Corresponding author.
Highlights |
• | Nabs and IgG S antibodies peaked 10–14 days post booster and stabilized in 60 days. |
• | Nabs against Omicron decreased 6.4-fold and IgG S antibodies 2.3-fold during peaks. |
• | Two doses of CoronaVac alone can't elicit sufficient Nab responses against Omicron. |
• | Three doses provided efficacy of 97.5% and 65.2% at 14 and 150 days, respectively. |
© 2022
Publié par Elsevier Masson SAS.
Vol 85 - N° 4
P. e119-e121 - octobre 2022 Retour au numéro
Article précédent
- SNX27-mediated endocytic recycling of GLUT1 is suppressed by SARS-CoV-2 spike, possibly explaining neuromuscular disorders in patients with COVID-19
- Yongwen Ren, Yihan Liu, Zhiwen Zhang, Yuwen Liu, Kangxin Li, Leiliang Zhang
- Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
- Mingyang Yang, Toni Li, Lihai Jiang, Yushu Wang, Carolyn Tran, Guangyu Ao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?